冷泉港亚洲（CSH Asia）2012：癌症的转化治疗与进展会议

Location: Suzhou, China
Dates: October 20-24, 2012
Website: http://www.csh-asia.org/differ12.html

• Saijuan Chen, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China
• Zhu Chen, Ministry of Health P.R. China / Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China
• Samuel Waxman, The Mount Sinai Medical Center, USA

This Cold Spring Harbor conference, merged with the biennial International Conference on Differentiation Therapy (ICDI), is recognized as one of the highest-level international scientific meetings in the field of cancer research. The conference focuses on differentiation therapy, which has shown a targeted, cancer-selective therapeutic effect, transforming acute promyelocytic leukemia from a highly fatal disease to a curable one. The conference aims to reflect the most updated advancements in differentiation cancer therapies.

• Epigenetics and Epigenomics
• Mechanism and impact on cancer therapy
• Genetics and Genomics of Cancer
• Cancer stem cells and novel targets
• Animal models and novel targets
• Targeted Therapies: Present and Future
• Differentiation Therapy of APL and Beyond

• Stephen Baylin, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, USA
• Zhu Chen, Ministry of Health P.R. China / Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China
• Carlo Croce, Ohio State University, USA
• Samuel Waxman, The Mount Sinai Medical Center, USA

• Saijuan Chen, Shanghai Institute of Hematology, Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, China
• John Crispino, Northwestern University, USA
• Riccardo Dalla-Favera, Columbia University, USA
• Hugues de Thé, Université Paris 7/CNRS, France
• Tariq Enver, UCL Cancer Institute, UK
• Lorraine Gudas, Weill Cornell Medical College, USA
• Zeguang Han, Shanghai Jiaotong University, China
• Gunther Hartmann, Universitätsklinikum Bonn, Germany
• Scott Hiebert, Vanderbilt University, USA
• Shai Izraeli, Sheba Medical Center, Israel
• Phillip Koeffler, National University of Singapore, Singapore
• Xin Lu, Ludwig Institute For Cancer Research Ltd, UK
• Ari Melnick, Weill Cornell Medical College, USA
• Tomoki Naoe, Nagoya University Graduate School of Medicine, Japan
• Benjamin Neel, Ontario Cancer Institute/MaRs Centre, Canada
• Ryuzo Ohno, Aichi Cancer Center Hospital, Japan
• Michael Rosenfeld, HHMI/University of California, San Diego, USA
• Yongfeng Shang, Tianjin Medical University, China
• Yang Shi, Harvard Medical School, USA
• Martin Tallman, Memorial Sloan-Kettering Cancer Center, USA
• Daniel Tenen, Cancer Science Institute of Singapore, NUS, Singapore
• Jun Wang, BIG-Shenzhen, China
• Yue Xiong, University of North Carolina at Chapel Hill, USA
• Arthur Zelent, Institute of Cancer Research, UK
• Yixin Zeng, Peking Union Medical College, China
• Qimin Zhan, Peking Union Medical College, China

• Cold Spring Harbor Asia
  No.299 Qiyue Road, SIP/ Suzhou, Jiangsu Province, China
  Tel: +86-512-62729029
  Fax: +86-512-62729028
  Email: mikeji@cshl.edu
  Website: www.csh-asia.org